Published by Josh White on 17th March 2022
(Sharecast News) - Inhaled antiviral treatment developer Synairgen said on Thursday that the US National Institute of Allergy and Infectious Diseases (NIAID) has halted all patient recruitment in its phase 2 and 3 Covid-19 trial, which included the assessment of its 'SNG001' treatment.
URL: http://www.digitallook.com/dl/news/story/32539640/...